GU Cancers Symposium 2014 - Does Gleason score predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer? An analysis of AA phase 3 trials - Poster

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Karim Fizazi, Thomas W. Flaig, Carsten-Henning Ohlmann, Howard I. Scher, Johann Sebastian De Bono, Dana E. Rathkopf, Charles J. Ryan, Thian San Kheoh, Jinhui Li, Mary Beth Todd, Thomas W. Griffin, Arturo Molina, and Michael Stöckle at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 Fizazi AA thumb

 

Institut Gustave Roussy, University of Paris Sud, Villejuif, France; University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO; Saarland University, Homburg/Saar, Germany; Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Janssen Research & Development, LLC, Los Angeles, CA; Janssen Research & Development, LLC, Raritan, NJ; Janssen Global Services, Raritan, NJ; Janssen Research & Development, LLC, Menlo Park, CA

 

email news signup